Oral pharmacologic treatment of type 2 diabetes mellitus

A clinical practice guideline update from the American college of physicians

for the Clinical Guidelines Committee of the American College of Physicians

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on oral pharmacologic treatment of type 2 diabetes in adults. This guideline serves as an update to the 2012 ACP guideline on the same topic. This guideline is endorsed by the American Academy of Family Physicians. Methods: This guideline is based on a systematic review of randomized, controlled trials and observational studies published through December 2015 on the comparative effectiveness of oral medications for type 2 diabetes. Evaluated interventions included metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Study quality was assessed, data were extracted, and results were summarized qualitatively on the basis of the totality of evidence identified by using several databases. Evaluated outcomes included intermediate outcomes of hemoglobin A1c, weight, systolic blood pressure, and heart rate; all-cause mortality; cardiovascular and cerebrovascular morbidity and mortality; retinopathy, nephropathy, and neuropathy; and harms. This guideline grades the recommendations by using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Target Audience and Patient Population: The target audience for this guideline includes all clinicians, and the target patient population includes adults with type 2 diabetes. Recommendation 1: ACP recommends that clinicians prescribe metformin to patients with type 2 diabetes when pharmacologic therapy is needed to improve glycemic control. (Grade: strong recommendation; moderate-quality evidence) Recommendation 2: ACP recommends that clinicians consider adding either a sulfonylurea, a thiazolidinedione, an SGLT-2 inhibitor, or a DPP-4 inhibitor to metformin to improve glycemic control when a second oral therapy is considered. (Grade: weak recommendation; moderate-quality evidence.) ACP recommends that clinicians and patients select among medications after discussing benefits, adverse effects, and costs.

Original languageEnglish (US)
Pages (from-to)279-290
Number of pages12
JournalAnnals of Internal Medicine
Volume166
Issue number4
DOIs
StatePublished - Feb 21 2017

Fingerprint

Practice Guidelines
Type 2 Diabetes Mellitus
Guidelines
Physicians
Metformin
Sodium-Glucose Transport Proteins
Dipeptidyl-Peptidase IV Inhibitors
Health Services Needs and Demand
Therapeutics
Blood Pressure
Thiazolidinediones
Mortality
Family Physicians
Observational Studies
Hemoglobins
Randomized Controlled Trials
Heart Rate
Databases
Morbidity
Weights and Measures

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Oral pharmacologic treatment of type 2 diabetes mellitus : A clinical practice guideline update from the American college of physicians. / for the Clinical Guidelines Committee of the American College of Physicians.

In: Annals of Internal Medicine, Vol. 166, No. 4, 21.02.2017, p. 279-290.

Research output: Contribution to journalArticle

for the Clinical Guidelines Committee of the American College of Physicians. / Oral pharmacologic treatment of type 2 diabetes mellitus : A clinical practice guideline update from the American college of physicians. In: Annals of Internal Medicine. 2017 ; Vol. 166, No. 4. pp. 279-290.
@article{b156c27022674d20a7cf720517dfb0af,
title = "Oral pharmacologic treatment of type 2 diabetes mellitus: A clinical practice guideline update from the American college of physicians",
abstract = "Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on oral pharmacologic treatment of type 2 diabetes in adults. This guideline serves as an update to the 2012 ACP guideline on the same topic. This guideline is endorsed by the American Academy of Family Physicians. Methods: This guideline is based on a systematic review of randomized, controlled trials and observational studies published through December 2015 on the comparative effectiveness of oral medications for type 2 diabetes. Evaluated interventions included metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Study quality was assessed, data were extracted, and results were summarized qualitatively on the basis of the totality of evidence identified by using several databases. Evaluated outcomes included intermediate outcomes of hemoglobin A1c, weight, systolic blood pressure, and heart rate; all-cause mortality; cardiovascular and cerebrovascular morbidity and mortality; retinopathy, nephropathy, and neuropathy; and harms. This guideline grades the recommendations by using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Target Audience and Patient Population: The target audience for this guideline includes all clinicians, and the target patient population includes adults with type 2 diabetes. Recommendation 1: ACP recommends that clinicians prescribe metformin to patients with type 2 diabetes when pharmacologic therapy is needed to improve glycemic control. (Grade: strong recommendation; moderate-quality evidence) Recommendation 2: ACP recommends that clinicians consider adding either a sulfonylurea, a thiazolidinedione, an SGLT-2 inhibitor, or a DPP-4 inhibitor to metformin to improve glycemic control when a second oral therapy is considered. (Grade: weak recommendation; moderate-quality evidence.) ACP recommends that clinicians and patients select among medications after discussing benefits, adverse effects, and costs.",
author = "{for the Clinical Guidelines Committee of the American College of Physicians} and Amir Qaseem and Barry, {Michael J.} and Linda Humphrey and Forciea, {Mary Ann} and Nick Fitterman and Cynthia Boyd and Carrie Horwitch and Alfonso Iorio and Devan Kansagara and Scott Manaker and McLean, {Robert M.} and Sandeep Vijan and Wilt, {Timothy J.}",
year = "2017",
month = "2",
day = "21",
doi = "10.7326/M16-1860",
language = "English (US)",
volume = "166",
pages = "279--290",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "4",

}

TY - JOUR

T1 - Oral pharmacologic treatment of type 2 diabetes mellitus

T2 - A clinical practice guideline update from the American college of physicians

AU - for the Clinical Guidelines Committee of the American College of Physicians

AU - Qaseem, Amir

AU - Barry, Michael J.

AU - Humphrey, Linda

AU - Forciea, Mary Ann

AU - Fitterman, Nick

AU - Boyd, Cynthia

AU - Horwitch, Carrie

AU - Iorio, Alfonso

AU - Kansagara, Devan

AU - Manaker, Scott

AU - McLean, Robert M.

AU - Vijan, Sandeep

AU - Wilt, Timothy J.

PY - 2017/2/21

Y1 - 2017/2/21

N2 - Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on oral pharmacologic treatment of type 2 diabetes in adults. This guideline serves as an update to the 2012 ACP guideline on the same topic. This guideline is endorsed by the American Academy of Family Physicians. Methods: This guideline is based on a systematic review of randomized, controlled trials and observational studies published through December 2015 on the comparative effectiveness of oral medications for type 2 diabetes. Evaluated interventions included metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Study quality was assessed, data were extracted, and results were summarized qualitatively on the basis of the totality of evidence identified by using several databases. Evaluated outcomes included intermediate outcomes of hemoglobin A1c, weight, systolic blood pressure, and heart rate; all-cause mortality; cardiovascular and cerebrovascular morbidity and mortality; retinopathy, nephropathy, and neuropathy; and harms. This guideline grades the recommendations by using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Target Audience and Patient Population: The target audience for this guideline includes all clinicians, and the target patient population includes adults with type 2 diabetes. Recommendation 1: ACP recommends that clinicians prescribe metformin to patients with type 2 diabetes when pharmacologic therapy is needed to improve glycemic control. (Grade: strong recommendation; moderate-quality evidence) Recommendation 2: ACP recommends that clinicians consider adding either a sulfonylurea, a thiazolidinedione, an SGLT-2 inhibitor, or a DPP-4 inhibitor to metformin to improve glycemic control when a second oral therapy is considered. (Grade: weak recommendation; moderate-quality evidence.) ACP recommends that clinicians and patients select among medications after discussing benefits, adverse effects, and costs.

AB - Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on oral pharmacologic treatment of type 2 diabetes in adults. This guideline serves as an update to the 2012 ACP guideline on the same topic. This guideline is endorsed by the American Academy of Family Physicians. Methods: This guideline is based on a systematic review of randomized, controlled trials and observational studies published through December 2015 on the comparative effectiveness of oral medications for type 2 diabetes. Evaluated interventions included metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Study quality was assessed, data were extracted, and results were summarized qualitatively on the basis of the totality of evidence identified by using several databases. Evaluated outcomes included intermediate outcomes of hemoglobin A1c, weight, systolic blood pressure, and heart rate; all-cause mortality; cardiovascular and cerebrovascular morbidity and mortality; retinopathy, nephropathy, and neuropathy; and harms. This guideline grades the recommendations by using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Target Audience and Patient Population: The target audience for this guideline includes all clinicians, and the target patient population includes adults with type 2 diabetes. Recommendation 1: ACP recommends that clinicians prescribe metformin to patients with type 2 diabetes when pharmacologic therapy is needed to improve glycemic control. (Grade: strong recommendation; moderate-quality evidence) Recommendation 2: ACP recommends that clinicians consider adding either a sulfonylurea, a thiazolidinedione, an SGLT-2 inhibitor, or a DPP-4 inhibitor to metformin to improve glycemic control when a second oral therapy is considered. (Grade: weak recommendation; moderate-quality evidence.) ACP recommends that clinicians and patients select among medications after discussing benefits, adverse effects, and costs.

UR - http://www.scopus.com/inward/record.url?scp=85017354932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017354932&partnerID=8YFLogxK

U2 - 10.7326/M16-1860

DO - 10.7326/M16-1860

M3 - Article

VL - 166

SP - 279

EP - 290

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 4

ER -